Nortech Systems is a Maple Grove electronics manufacturing services shop trying to prove that a two-year plant reset can turn medical-device demand into cash rather than just fuller factories. Management closed the Blue Earth, Minnesota plant, moved programs into Bemidji and Monterrey, and refinanced after Bank of America waived year-end covenant breaches. Second-quarter sales rose as medical programs ramped, yet operating profit still receded because incentive pay clawed back the absorption gain. The investment debate is whether this is a durable earnings rebuild or a high-mix contractor that prints better gross margin only while inventory and receivables absorb the cash.
The print itself is a mixed verdict on that question. Net sales reached $33.5 million, up from the year-ago quarter, with Medical Device the engine after existing customers and new programs ramped. Gross margin expanded to 17 percent on better factory absorption. Operating income still fell because incentive compensation swung from a prior-year reversal into a current-period accrual. That pattern matters: the factories are busier, but the income statement has not yet shown that busier plants drop more profit to the residual claim.
Cash is the unresolved test. Total backlog climbed to $93.8 million, and the ninety-day book is also higher than a year earlier, which supports the near-term shipment case. Operations still used $2.4 million of cash in the first half as inventory and contract assets rose to feed that book. The Associated Bank facility replaced the prior revolver and left modest unused availability against a thin cash balance. Whether backlog conversion funds itself, or whether the line of credit remains the working-capital backstop, is the question the next several quarters resolve.